Q-Med terminates collaboration with Medy-Tox Inc.

Q-Med terminates collaboration with Medy-Tox Inc.

Q-Med AB and Medy-Tox Inc., a pharmaceuticals company based in South Korea, have
together decided to terminate the collaboration that the parties entered into
during 2007. The collaboration comprised the development and commercialization
of new products based on botulium toxin and potential for Q-Med to distribute 
Medy-Tox's existing botulinum toxin type A product. 

The parties have both signed a separation agreement, amongst other things, where
they agree to a financial settlement which entails Medy-Tox repaying the
majority of the loan that Q-Med has given the company up until the present date.
Further details concerning the repayment will not be made public, however.

The parties' original agreement included Q-Med giving Medy-Tox a loan of up to 
3 MUSD for the adaptation of facilities and manufacturing processes, and paying
up to 8 MUSD on condition that certain commercial objectives were achieved. 

Q-Med still aims to continue work on the development and commercialization of
products within the botulinum toxin area. 


Queries should be addressed to: 
Alexander Kotsinas, Vice president and CFO
Tel: +46 (0)73 500 11 11
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: + 46 (0)70 974 90 15


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.